Is a
Patent attributes
Current Assignee
Patent Jurisdiction
Patent Number
Date of Patent
August 18, 2009
Patent Application Number
11578614
Date Filed
May 2, 2005
Patent Citations Received
Patent Primary Examiner
Patent abstract
The invention provides specific FGF-21 compounds fused to specific IgG4-Fc or HSA derivatives resulting in fusion proteins that are biologically active with an extended elimination half-life and a slower clearance. These FGF-21 compound fusion proteins and compositions are useful in treating type 2 diabetes, obesity, and metabolic syndrome.
Timeline
No Timeline data yet.
Further Resources
No Further Resources data yet.
